Senores Pharma: Strong Growth and a Clear Path to FY26-27 Expansion
Moneylife Digital Team 28 January 2026
Senores Pharmaceuticals (Senores) delivered strong Q3FY25-26 results, with consolidated revenue rising 69% year-on-year (y-o-y) to ₹175 crore. Earnings before interest, taxes, depreciation and...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback